Lei Wen1, Yi-Ze Li1, Jing Zhang1, Cheng Zhou2, Hai-Nan Yang3, Xin-Zu Chen4, Long-Wen Xu5, Sheng-Nan Kong1, Xiao-Wen Wang1, Hong-Mei Zhang1. 1. Department of Clinical Oncology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi Province, PR China. 2. Department of Oncology, Sanjiu Brain Hospital, Guangzhou, Guangdong Province, PR China. 3. Department of Medical Oncology, Ninth School of Clinical Medicine, Peking University, Beijing, 100038, PR China. 4. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan Province, PR China. 5. Department of Renal Cancer & Melanoma, Peking University Cancer Hospital, Beijing, PR China.
Abstract
Aim: We evaluated the incidence, clinicopathological features, prognostic factors and survival of gastric cancer (GC) with bone metastasis in a single large cancer center in China. Patients & methods: Patients with bone metastasis of GC were retrospectively analyzed. Overall survival was estimated using the Kaplan-Meier method. Clinicopathological factors, which were associated with prognostic factors for survival, were evaluated. Results: The incidence of bone metastasis was 11.3% for metastatic GC patients. Median overall survival time was 6.5 months. Multivariate analysis revealed two independent poor prognostic factors: Eastern Cooperative Oncology Group ≥2 (p = 0.023) and lack of palliative chemotherapy (p = 0.018). Conclusion: The incidence of bone metastasis from metastatic GC was underestimated. The prognosis of GC with bone metastasis was poor.
Aim: We evaluated the incidence, clinicopathological features, prognostic factors and survival of gastric cancer (GC) with bone metastasis in a single large cancer center in China. Patients & methods: Patients with bone metastasis of GC were retrospectively analyzed. Overall survival was estimated using the Kaplan-Meier method. Clinicopathological factors, which were associated with prognostic factors for survival, were evaluated. Results: The incidence of bone metastasis was 11.3% for metastatic GC patients. Median overall survival time was 6.5 months. Multivariate analysis revealed two independent poor prognostic factors: Eastern Cooperative Oncology Group ≥2 (p = 0.023) and lack of palliative chemotherapy (p = 0.018). Conclusion: The incidence of bone metastasis from metastatic GC was underestimated. The prognosis of GC with bone metastasis was poor.
Entities:
Keywords:
bone metastasis; gastric cancer; incidence